Rapport Therapeutics (NASDAQ:RAPP) Sets New 12-Month Low – Here’s Why

Rapport Therapeutics (NASDAQ:RAPP) shares hit a new 52-week low on Tuesday . The company traded as low as $12.98 and last traded at $13.97, with a volume of 141904 shares trading hands. The stock had previously closed at $14.81.

Rapport Therapeutics Stock Up 5.1 %

The business’s 50 day moving average price is $20.26 and its 200-day moving average price is $21.42.

Institutional Investors Weigh In On Rapport Therapeutics

A number of institutional investors have recently modified their holdings of the company. Values First Advisors Inc. purchased a new stake in Rapport Therapeutics during the third quarter worth about $31,000. BNP Paribas Financial Markets purchased a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $34,000. JPMorgan Chase & Co. purchased a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $83,000. SG Americas Securities LLC acquired a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $101,000. Finally, Sandia Investment Management LP purchased a new position in Rapport Therapeutics in the 2nd quarter valued at approximately $116,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.